Biomass conversion could open 295bn US-$ market by 2030


Geneva – Conversion of biomass to biofuels, chemicals, energy and heat has the potential to create a US$295 bn market by the year 2030 and create 800,000 new jobs, according to a report published by the World Economic Forum (WEF). The report, published in co-operation with the industrial biotechnology companies Royal DSM, Novozymes, the chemical corporation DuPont and the plastics manufacturer Braskem, sees huge potential particularly in building biorefineries that convert renewable resources carbon dioxide neutrally into energy, biofuels, chemicals and bioplastics. The report „The Future of Industrial Biorefinieries“ estimates that creation of a biomass value chain can generate revenues of US$15m for agricultural inputs, US$89bn for biomass production, US-$30 for biomass trading, US-$ 10bn for berefining inputs, US-$ 80 bn for fermentation of biofuels, US$6bn for bioplastic production, and US$65bn for biomass-based power and heat. However, the report also says that high investment and infrastructure costs as well as restricted availability of biomass could hamper biomass conversion to become a commercial success at the industry scale. On the other side, biorefineries have the potential to reshape today’s industrial landscape.“ We are at the doorstep of a transition to a greener, more sustainable future, with the bio-based economy as the key enabler“ commented Feike Sijbesma, CEO of DSM, the world leader in fermentative biomass conversion. The report confirms he need for biomass replacement that comes at oil’s low prices but without the high cost.“ Said Stehen Rijsgaard, CEO of Novozymes, the world champion in enzyme technology. Braskem is planning a production site in Brazil to produce biobased polyethylene at 200.000 metric tons per year. DuPont has produced the platform chemical 1,3 propane diol (PDO) on an industrial scale since 2006, while Novozymes has developed an enzyme cocktail for biofuel production from wood waste and grass.



Liestal – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published the results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly...



Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the...



Reinach – Evolva SA has got its hands on up to €30m of fresh capital. The Swiss specialist for synthetic biology announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA...



Basel/Waltham - Expecting to be bought by Novartis, U.S. biopharmaceutical firm Proteon Therapeutics Inc. has delivered a new $15.2 million financing. The Swiss pharmaceutical company Novartis obtained exclusive option to acquire...



Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and...



A big financier of biotech deals could be back on track soon. Novartis is interested in further acquisitions, CEO Joe Jimenez said in an interview published by the "Aargauer Zeitung", a Switzerland- based newspaper.The drugmaker...



Basel – Swiss crop group Syngenta plans to construct a new biotech research facility adjacent to its existing research campus at the Research Triangle Park in North Carolina (US). The US$71m investment is scheduled to begin in...

Displaying results 31 to 40 out of 276

< Previous 31-40 Next >

© 2007-2015 BIOCOM



Product of the week



All Events

Stock list

All quotes


  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%


  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%


  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%


  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%


  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%


  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015

Current issue

All issues